Hela wins Flemingsberg Science Award

Hela is a company that is developing a mobile application that helps people with heart conditions improve their cardiac rehabilitation. The app encourages daily exercise, provides care support, and the ability to monitor progress.

The Flemingsberg Science Award is a sub-competition of Venture Cup, Sweden’s largest entrepreneurship competition. The Flemingsberg Science STARTUP Award is awarded to people behind startups with an established connection to Flemingsberg, either as students, residents or who are in other ways active in the area.

This year’s winner is Hela, which, with experience from Silicon Valley in the US, has developed an app for improving and facilitating cardiac rehabilitation.

“This win is primarily recognition but it also provides valuable visibility because we tend to focus more on product development than on marketing,” says Asmen Gül, Hela founder.

The app should make it possible to keep track of daily training activity and obtain an accurate picture of daily progress with a specially developed programme.

“We increase commitment to cardiac rehabilitation by visualising improvements in patients’ health during the programme. We have different revenue models depending on the market, but we mainly target private cardiac rehabilitation centres and cardiac-specific physiotherapists.”

Now the offering will be scaled up to suit more users. The application also provides the option of individual support from healthcare staff and includes a community where users can support each other.

“The next step is to enter into agreements with regional authorities to scale up the service, and collaborate with medtech companies on diagnostic products. We’ll do this using test pilots who demonstrate increased patient commitment across a number of different parameters,” says Gül.

Learn more about Hela here and see how the app works here.

AlzeCure Pharma – a hope in the fight against Alzheimer’s

Neurological diseases and the pain area are struggling with great medical needs, including the lack of broad-spectrum drugs. Those are gaps in the market that AlzeCure Pharma wants to fill, and they are well on their way. They recently received a grant from the European Innovation Council (EIC) to finance a clinical phase 2 study of the drug candidate NeuroRestore ACD856 for Alzheimer’s disease.

Kick-off Cluster Engine Life Science Flemingsberg!

At the end of last year, the Flemingsberg Science Foundation was granted funding from the European Regional Development Fund (ERDF) for the project Cluster Engine Life Science Flemingsberg, which aims to strengthen the growth and establishment of small and medium-sized enterprises (SMEs) within the life science sector in the Stockholm region. Recently, it was time for the official launch – and what a grand launch it was!

Flemingsberg Expands with Huge Bostäder

Imagine a home where The Royal Swedish Opera and The Royal Dramatic Theatre’s studios are in your front yard, and the Flemingsberg Forest Nature Reserve and Lake Gömmaren are in your back yard. Where Campus Flemingsberg is your neighbor to the left, and a modernized shopping center your neighbor to the right. Too good to be true? Not at all!

Do you want to know more?
Subscribe to our newsletter.

Do you want to know more?
Subscribe to our newsletter.

CF_logo_neg
2022-06-23T08:56:27+02:00
Go to Top